LONDON, NEW YORK and HAMILTON, BERMUDA, 15 October 2007 -- Celtic Pharmaceutical Holdings L.P. (“Celtic Pharma”), the global private equity firm focused on the biotechnology and pharmaceutical industries, announced today the enrollment of the first patient into the Phase II trial of TDT-067, terbinafine in Transfersomes®, for the treatment of onychomycosis. This is an open-label study to explore the efficacy and safety of topically applied terbinafine delivered through the Transfersome® targeted delivery technology. Celtic Pharma acquired an exclusive global licence to IDEA AG’s Transfersome® technology in February 2006.
